No Data
No Data
12 Health Care Stocks Moving In Thursday's After-Market Session
AIM ImmunoTech Granted U.S. Patent for Ampligen for the Treatment of Endometriosis
Express News | AIM ImmunoTech Granted U.S. Patent for Ampligen® for the Treatment of Endometriosis
Express News | AIM ImmunoTech Inc - Class C and D Warrants Exercisable at $0.28 Each
Express News | AIM ImmunoTech Inc - to Issue Class C and D Warrants
Express News | AIM ImmunoTech Announces Pricing of $1.26 Million Registered Direct Offering
No Data
No Data